UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.80. The company’s ...

GSK's Q4 sales hit $10.40 billion, topping estimates. Specialty Medicines grew 14%, while vaccines declined. The company ...

Mark Hartley weighs up the growing potential in GSK as its share price makes rare gains following a promising set of results.

GSK’s 6% results-day share price advance is the standout performance in an otherwise subdued FTSE 100 index. Miner Fresnillo ...

In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price ...

Glaxo (GSK) delivered earnings and revenue surprises of 11.32% and 4.04%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

On Monday, GSK plc (GSK) stock saw a decline, ending the day at $34.9 which represents a decrease of $-0.37 or -1.05% from the prior close of $35.27. The stock opened at $34.87 and touched a low of ...

Stock prices in London were mixed on Wednesday afternoon, with a share price rise for GSK supporting the FTSE 100, though tariff worries continue to hang over equities. The FTSE 100 index rose 12.01 ...

London stocks were still a touch higher by midday on Wednesday as investors continued to mull the impact of Trump’s trade war ...

European markets opened mixed on Wednesday, with investors looking ahead to more earnings from a number of key companies.

Strong full-year trading and an improving outlook have propelled GSK's share price higher, as Royston Wild explains. The post ...